

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

WEST CHESTER, PA – May 26, 2021 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. ET.

Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/jeff174/vrca/1848852

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis

Chief Financial Officer 484.453.3300 ext. 103 info@verrica.com

William Windham

Solebury Trout 646.378.2946 wwindham@soleburytrout.com

Media:

Zara Lockshin

Solebury Trout 646.378.2960 zlockshin@soleburytrout.com